Portugal – Antineoplastic and immunomodulating agents – 2023/0491 - RITUXIMAB [120 MG/ ML; 11,7 ML; FRS]

Unlock Full Tender Insight

Complete details, deadlines, and AI-powered analysis are available inside the tend.ee platform. Create your free account to access.

It's free to get started. No credit card required.